. Author manuscript; available in PMC: 2020 Oct 15.

Published in final edited form as: Pediatr Blood Cancer. 2019 Oct 8;67(1):e28028. doi: 10.1002/pbc.28028

TABLE 2.

Targeted therapies that have undergone evaluation or are currently in clinical trials for pediatric CNS tumors

Target	Targeted Agent	Clinical Trial Number
BRAF	Dabrafenib Vemurafenib	NCT01677741, NCT02684058, NCT03919071 NCT01748149, NCT03220035, NCT01596140
CDK4/6	Abemaciclib Ribociclib⁴⁰ Palbociclib	NCT02644460 NCT03387020, NCT03355794, NCT02607124, NCT03434262 NCT03526250, NCT03155620
ERK	Ulixertinib	NCT03698994, NCT03155620
FGFR1/2/3/4	Erdafitinib	NCT03210714, NCT03155620
MEK1/2	Trametinib Selumetinib⁴¹ Cobimetinib	NCT02124772, NCT02684058, NCT03363217, NCT03919071, NCT03434262 NCT03213691, NCT01089101, NCT03871257, NCT03155620 NCT02639546, NCT02693535
mTOR, PIK3CA	Everolimus⁴² Sirolimus LY3023414	NCT02155920, NCT01734512, NCT03355794, NCT03387020, NCT03245151 NCT01331135, NCT01135563, NCT02574728 NCT03213678, NCT03155620
PDGFRA	Imatinib, Dasatinib	NCT00021229 NCT01644773, NCT03352427, NCT02389309, NCT00996723
NTRK1/2/3, ROS1, ALK	Entrectinib, Larotrectinib⁴³ Ensartinib, Crizotinib	NCT02650401, NCT03066661 NCT03213704, NCT02637687, NCT03025360, NCT02576431 NCT03213652, NCT03155620 NCT01644773
VEGF	Bevacizumab	NCT02840409, NCT01884740, NCT00883688, NCT00756340, NCT00879437